Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-85 years,~* Admitted to the hospital because of confirmed positive SARS-CoV-2 (COVID-19 infection).~* Evidence of pulmonary involvement on CT scan or X-Ray of the chest,~* Symptom onset within the previous 10 days AND at least one additional risk factor for progression to mechanical ventilation: 1) arterial hypertension, 2) \>50 years, 3) obesity (BMI\>30.0 kg/m2), 4) history of cardiovascular disease, 5) chronic pulmonary disease, 7) chronic renal disease, 6) C-reactive protein of \>35mg/L, 7) oxygen saturation at rest in ambient air of \<94%~Exclusion Criteria:~* Contraindications to the class of drugs under study (C1 esterase inhibitor);~* History or suspicion of allergy to rabbits;~* Women who are of childbearing potential and not using methods of contraception during the entire study period;~* Pregnant or breastfeeding females or has a positive serum β-human chorionic gonadotropin (hCG) pregnancy test at screening;~* Chronic liver disease (any Child-Pugh score B or C);~* Currently admitted to an ICU or expected admission within the next 24 hours; and~* Currently receiving invasive or non-invasive ventilation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ruconest (Type: EXPERIMENTAL): Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.
- Standard of Care (Type: OTHER): SOC

Based on this trial design, predict the completion outcome and termination type (if applicable).